57. Idiopathic dilated cardiomyopathy Clinical trials / Disease details
Clinical trials : 11 / Drugs : 23 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02987322 (ClinicalTrials.gov) | November 2015 | 29/11/2016 | Honey in Idiopathic Dilated Cardiomyopathy | Honey Supplementation in Children With Idiopathic Dilated Cardiomyopathy: A Randomized Controlled Study | Idiopathic Dilated Cardiomyopathy | Dietary Supplement: honey | mamdouh abdulmaksoud abdulrhman | NULL | Completed | 2 Years | 12 Years | Both | 50 | Phase 2/Phase 3 | NULL |
| 2 | NCT02033278 (ClinicalTrials.gov) | January 6, 2014 | 9/1/2014 | Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. | Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. | Idiopathic Dilated Cardiomyopathy | Drug: Infusion of autologous mononuclear bone marrow cells;Drug: Placebo infusion | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Iniciativa Andaluza en Terapias Avanzadas | Terminated | 18 Years | 70 Years | All | 27 | Phase 2 | Spain |
| 3 | NCT02256501 (ClinicalTrials.gov) | June 2013 | 1/10/2014 | Intracoronary Transplantation of Bone Marrow Derived Mononuclear Cells in Pediatric Cardiomyopathy | Intracoronary Transplantation of Autologous Bone Marrow Derived Mononuclear Cells (MNC) in Idiopathic Dilated Cardiomyopathy in Pediatric Patients: Clinical Trial Phase I/II | Cardiomyopathy | Biological: Mono Nuclear Cell (MNC) transplantation | Nasser Aghdami MD., PhD | NULL | Completed | 1 Year | 16 Years | All | 30 | Phase 1/Phase 2 | Iran, Islamic Republic of |
| 4 | NCT02292043 (ClinicalTrials.gov) | May 2013 | 31/10/2014 | Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction | Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction | Congestive Heart Failure | Drug: HTEA | Harbin Medical University | NULL | Recruiting | 20 Years | 80 Years | Both | 60 | N/A | China |
| 5 | NCT01219452 (ClinicalTrials.gov) | October 2010 | 12/10/2010 | Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy | Effects of Intramuscular Injection of Umbilical Cord Mesenchymal Stem Cell on the Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Biological: umbilical cord mesenchymal stem cells | Qingdao University | NULL | Not yet recruiting | 1 Year | 14 Years | Both | 30 | Phase 1/Phase 2 | China |
| 6 | NCT01302171 (ClinicalTrials.gov) | August 2010 | 21/2/2011 | Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy | Randomised Controlled Trial to Compare the Effects of G-CSF (Granocyte™) and Autologous Bone Marrow Progenitor Cells on Quality of Life and Left Ventricular Function in Patients With Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Drug: granulocyte colony stimulating factor (GCSF);Procedure: bone marrow mononuclear cells | Barts & The London NHS Trust | Royal Brompton & Harefield NHS Foundation Trust;University College London Hospitals | Completed | 18 Years | 80 Years | Both | 60 | Phase 2 | United Kingdom |
| 7 | EUCTR2009-013112-12-GB (EUCTR) | 22/04/2010 | 17/03/2010 | Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dilated Cardiomyopathy - REGENERATE-DCM | Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dilated Cardiomyopathy - REGENERATE-DCM | Idiopathic Dilated Cardiomyopathy Level: LLTClassification code 10056419Term: Dilated Cardiomyopathy | Trade Name: Granocyte Lenograstim Product Name: GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) Product Code: PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | Barts & the London NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 8 | NCT02115581 (ClinicalTrials.gov) | September 2006 | 22/12/2008 | Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy | Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial | Dilated Cardiomyopathy | Drug: Coenzyme Q10;Drug: Placebo | University of Tehran | NULL | Completed | 6 Months | 18 Years | All | 38 | Phase 4 | Iran, Islamic Republic of |
| 9 | NCT01917149 (ClinicalTrials.gov) | March 2005 | 30/7/2013 | Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy | Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Drug: Benazepril;Drug: Valsartan;Drug: Metoprolol | Xijing Hospital | NULL | Completed | 18 Years | 70 Years | Both | 480 | Phase 4 | China |
| 10 | NCT00281255 (ClinicalTrials.gov) | June 2003 | 20/1/2006 | Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy | Allopurinol and Cardiac Function Pilot Study in Idiopathic Dilated Cardiomyopathy | Cardiovascular Diseases;Cardiomyopathy, Dilated;Heart Diseases;Heart Failure, Congestive | Drug: Allopurinol;Drug: Dobutamine | University of Pennsylvania | National Heart, Lung, and Blood Institute (NHLBI) | Withdrawn | 18 Years | N/A | Both | 0 | Phase 1/Phase 2 | United States |
| 11 | NCT01798992 (ClinicalTrials.gov) | September 2000 | 22/2/2013 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart | Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart | Idiopathic Dilated Cardiomyopathy | Drug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosin | University of Colorado, Denver | National Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZeneca | Completed | 18 Years | N/A | All | 56 | Phase 4 | United States |